Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis.  Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

NASH

NASH (nonalcoholic steatohepatitis) is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases in man.  NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.  

SRT-015

NASH (nonalcoholic steatohepatitis) is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases in man.  NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.  

OUR TEAM

Seal Rock’s founders and management have held scientific and leadership roles in public and private biotech and pharma companies and have been involved in the discovery and development of numerous FDA-approved drugs.  Seal Rock's scientific advisers are internationally recognized experts in NASH.